Roivant Sciences ROIV
NASDAQ ROIV
$34.65 +0.24 (+0.68%)
As of: Sep 4, 2026 · 1:36 PM EDT

Roivant Sciences (ROIV) Interest Expenses (2022 - 2024)

Roivant Sciences' (ROIV) quarterly Interest Expenses came in at $1.6 billion in Q1 2026, up 127.74% YoY from $701.2 million in Q1 2025, and up 2419495.45% on a QoQ basis from $66000.0 in Q3 2025.

Analysis

Roivant Sciences (ROIV) Interest Expenses (2022 - 2024) Analysis & Trends

Roivant Sciences (ROIV) has 7 years of Interest Expenses data on file, last reported at $1.6 billion in Q1 2026.

  • Quarterly Interest Expenses rose 127.74% year-over-year to $1.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 billion (up 127.74% YoY) and the FY2026 annual result came in at $1.6 billion, up 127.74% from the prior year.
  • Interest Expenses improved to $1.6 billion in Q1 2026, from $66000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $1.6 billion in Q1 2026 to a low of $66000.0 in Q3 2025.
  • A 5-year average of $171.3 million and a median of $15.6 million in 2022 frame the typical range for Interest Expenses.
  • The widest YoY moves for Interest Expenses: up 5965.38% in 2025, down 99.94% in 2025.
  • Tracing ROIV's Interest Expenses over 5 years: stood at $19.4 million in 2022, then jumped by 42.33% to $27.6 million in 2023, then surged by 310.1% to $113.2 million in 2024, then tumbled by 99.94% to $66000.0 in 2025, then soared by 2419495.45% to $1.6 billion in 2026.
  • The last three Interest Expenses figures came in at $1.6 billion (Q1 2026), $66000.0 (Q3 2025), and $184000.0 (Q2 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Interest Expense (Qtr)
1 Vertex Pharmaceuticals 139.31 Bn 131.46 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.65 Bn 77.66 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.46 Bn 58.27 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.94 Bn 52.80 Bn 52.00 Mn -
5 Revolution Medicines 44.05 Bn 44.05 Bn - 23.78 Mn
6 BeOne Medicines 39.96 Bn 34.86 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.16 Bn 31.85 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.44 Bn 27.60 Bn - 93.62 Mn
9 Insmed 27.32 Bn 26.16 Bn 358.27 Mn 20.27 Mn
10 Roivant Sciences 24.96 Bn 24.96 Bn 1.16 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2024 13.40 Mn
Dec 31, 2023 27.60 Mn
Sep 30, 2023 9.25 Mn
Jun 30, 2023 8.91 Mn
Dec 31, 2022 19.39 Mn
Sep 30, 2022 8.34 Mn
Jun 30, 2022 2.61 Mn